Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 25, 2017
What is the competitive landscape for LILLY, and what generic alternatives to LILLY drugs are available?
LILLY has one hundred and thirty approved drugs.| Patents: | 26 |
| Tradenames: | 119 |
| Ingredients: | 102 |
| NDAs: | 130 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
pemetrexed disodium | For Injection | 750 mg/vial | ALIMTA | 10/6/2016 |
teriparatide | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | FORTEO | 7/27/2015 |
pemetrexed disodium | For Injection | 1000 mg/vial | ALIMTA | 6/27/2012 |
duloxetine hydrochloride | Delayed-release Capsules | 40 mg | CYMBALTA | 5/10/2012 |
tadalafil | Tablets | 2.5 mg | CIALIS | 10/14/2008 |
duloxetine hydrochloride | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | CYMBALTA | 8/4/2008 |
pemetrexed disodium | For Injection | 100 mg/vial | ALIMTA | 7/1/2008 |
olanzapine and fluoxetine hydrochloride | Capsules | 3 mg/25 mg | SYMBYAX | 5/8/2008 |
pemetrexed disodium | For Injection | 500 mg/vial | ALIMTA | 2/4/2008 |
tadalafil | Tablets | 5 mg, 10 mg and 20 mg | CIALIS | 11/21/2007 |
gemcitabine | For Injection | 2 g/vial | GEMZAR | 8/24/2007 |
atomoxetine hydrochloride | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | STRATTERA | 5/29/2007 |
gemcitabine | For Injection | 1g/vial | GEMZAR | 11/14/2005 |
gemcitabine | For Injection | 200 mg/vial | GEMZAR | 11/1/2005 |
olanzapine and fluoxetine hydrochloride | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | SYMBYAX | 1/10/2005 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
| ► Subscribe | ► Subscribe |
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,857,791 | Medication dispensing apparatus with gear set having drive member accommodating opening | ► Subscribe | |||||||||||||
| 4,996,206 | N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives | ► Subscribe | |||||||||||||
| 6,369,059 | Tetracyclic derivatives, process of preparation and use | ► Subscribe | |||||||||||||
| 6,608,065 | Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction | ► Subscribe | |||||||||||||
| 6,143,746 | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use | ► Subscribe | |||||||||||||
| 5,981,527 | Cyclic GMP-specific phosphodiesterase inhibitors | ► Subscribe | |||||||||||||
| 6,841,167 | .beta.-carboline pharmaceutical compositions | ► Subscribe | |||||||||||||
| 5,248,775 | Pyrrolo(2,3-d)pyrimidines | ► Subscribe | |||||||||||||
| 6,025,494 | Tetracyclic derivatives, process of preparation and use | ► Subscribe | |||||||||||||
| 7,427,275 | Medication dispensing apparatus with triple screw threads for mechanical advantage | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Israel | 146098 | ► Subscribe | |||||||||||||
| Canada | 2181377 | ► Subscribe | |||||||||||||
| China | 1513452 | ► Subscribe | |||||||||||||
| Russian Federation | 2142463 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 0108687 | ► Subscribe | |||||||||||||
| European Patent Office | 0846118 | ► Subscribe | |||||||||||||
| New Zealand | 333913 | ► Subscribe | |||||||||||||
| China | 1112928 | ► Subscribe | |||||||||||||
| Indonesia | 25704 | ► Subscribe | |||||||||||||
| Slovakia | 3898 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 213 | Luxembourg | ► Subscribe | PRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE | ||||||||||||
| 12/008 | Ireland | ► Subscribe | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 | ||||||||||||
| C0020 | France | ► Subscribe | PRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110 | ||||||||||||
| 2004005 | Lithuania | ► Subscribe | PRODUCT NAME: INSULIN DETEMIR | ||||||||||||
| 2004005,C0792290 | Lithuania | ► Subscribe | PRODUCT NAME: INSULIN DETEMIR; REGISTRATION NO/DATE: EU/1/04/278/001, EU/1/04/278/002, EU/1/04/278/003, EU/1/04/278/004, EU/1/04/278/005, EU/1/04/278/006, EU/1/04/278/007, EU/1/04/278/008, EU/1/04/278/00 20040601 | ||||||||||||
| C0025 | Belgium | ► Subscribe | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 | ||||||||||||
| C/GB05/011 | United Kingdom | ► Subscribe | PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920 | ||||||||||||
| /2008 | Austria | ► Subscribe | PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713 | ||||||||||||
| C/GB96/058 | United Kingdom | ► Subscribe | PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927 | ||||||||||||
| 2013000061 | Germany | ► Subscribe | PRODUCT NAME: INSULIN DEGLUDEC IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/807/001 EU/1/12/807/004-005 EU/1/12/807/007-009 EU/1/12/807/012-013 EU/1/12/807/015 20130121 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,766 others who get our Drug Patent Expiration Alerts:
